NCT03974243已完成1 期
Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2019年7月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- dose-limiting toxicity (DLT)
研究概览
简要总结
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib and Chidamide administered orally over a range of doses in patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the pharmacodynamic profile and latent biomarkers accompany with Chiauranib and Chidamide , as well as the relevancy of which and clinical benefit.
详细描述
The purpose of this study is to assess the tolerability and safety include adverse events, vital signs, laboratory tests ,etc., of a range of doses of Chiauranib and Chidamide in patients with relapsed or refractory non-Hodgkin's lymphoma, and to determine the dose limit toxicity and the maximum tolerable dose.
In the meantime, exploring the pharmacodynamic profile and latent biomarkers accompany with Chiauranib and Chidamide , as well as the relevancy of which and clinical benefit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female, aged ≥ 18 yrs and ≤70 yrs;
- •Patients with NHL refractory to at least 2 different chemotherapies , for which no standard therapy exists;
- •At least 1 lesion can be accurately measured, as defined by Lugano 2014 criteria.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
- •Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, immunotherapy and surgical therapy, et al) should beyond 4 weeks prior to study entry; Subjects received mitomycin chemotherapy should beyond 6 weeks prior to study entry; Subjects received autologous stem cell transplantation should beyond 3 months prior to study entry;
- •Laboratory criteria are as follows:
- •Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×109/L ; platelets >=90×109/L Biochemistry test: total bilirubin≦1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≦1.5×ULN; (ALT,AST≦5×ULN if liver involved) ;serum creatinine(cr)≦1.5×ULN; Coagulation test: International Normalized Ratio (INR) < 1.5
- •Life expectancy of at least 3 months.
- •Willingness to sign a written informed consent document.
排除标准
- •Clinical evidence of central nervous system involvement
- •Patients with prior invasive malignancies with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years;
- •Previous treatment with HDAC inhibitors(include Chidamide) or aurora kinase(include Chiauranib) inhibitors;
- •Have uncontrolled or significant cardiovascular disease, including:
- •Congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months prior to study entry; arrhythmia, or Left Ventricular Ejection Fraction (LVEF) < 50% requiring treatment with agents during screening stage.
- •primary cardiomyopathy(dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al)
- •History of significant QT interval prolongation, or Corrected QT Interval (QTc) > 450 ms prior to study entry
- •Symptomatic coronary heart disease requiring treatment with agents
- •Uncontrolled hypertension (> 140/90 mmHg) by single agent;
- •Have active bleeding current thrombotic disease, patients with bleeding potential ,or receiving anticoagulation therapy; within 2 months prior to screening;
- •Proteinuria positive(≥1g/24h);
- •History of deep vein thrombosis or pulmonary embolism;
- •Have unsolved toxicities (> grade 1) from prior anti-cancer therapy;
- •Have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption of oral agents, or patients undergone gastrectomy;
- •History of organ transplantation ，Allogeneic bone marrow transplantation or autologous stem cell transplantation;
- •High-risk surgery for vital organs within 6 weeks prior to screening or the investigators determined that other surgical wounds did not heal well;
- •Serologically positive for HIV, hepatitis B or C, or other serious infectious diseases;
- •History of interstitial lung disease(ILD);
- •Any mental or cognitive disorder, that would impair the ability to understand the informed consent document or the operation and compliance of study;
- •Candidate with drug and alcohol abuse;
- •Participants of reproductive potential not willing to use adequate contraceptive measures for the duration of the study (both male and female participants).Pregnant or breastfeeding women. Female participants must have a negative urinary or serum pregnancy test when done or have evidence of post-menopausal status (Defined as absence of menstruation for greater than 12 months, bilateral oophorectomy or hysterectomy);
- •Any other condition which is inappropriate for the study in the opinion of the investigators.
研究组 & 干预措施
treatment group
Experimental
In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.
Intervention: Drug: Chiauranib and Chidamide
干预措施: Chiauranib (Drug)
treatment group
Experimental
In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.
Intervention: Drug: Chiauranib and Chidamide
干预措施: Chidamide (Drug)
结局指标
主要结局
dose-limiting toxicity (DLT)
时间窗: Day 1 - 28
次要结局
- time to progression(About 21 weeks)
- Area under the concentration versus time curve (AUC)(Day 1 of the lead-in period and Day 1 of the combination therapy)
- Time of Cmax (Tmax)(Day 1 of the lead-in period and Day 1 of the combination therapy)
- disease control rate(About 21 weeks)
- Progression free survival(About 21 weeks)
- Peak plasma concentration (Cmax)(Day 1 of the lead-in period and Day 1 of the combination therapy)
- complete response rate(About 21 weeks)
- Objective response rate(About 21 weeks)
- Duration of response(About 21 weeks)
- Mutation of polygene and copy number variation in signal pathway(multi-gene analysis)(day -1 of therapy)
- Adverse events(About 21 weeks)
- Any single mutation of oncogene and copy number variation in ctDNA(single gene analysis)(day -1 of therapy)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I Study of Chiauranib in Patients With Advanced Solid TumorsSolid TumorsNCT02122809Chipscreen Biosciences, Ltd.18
已完成
1 期
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04742101Institut de Recherches Internationales Servier57
撤回
1 期
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaChronic B-cell Lymphocytic LeukemiaSmall Lymphocytic LeukemiaNCT02556346Molecular Templates, Inc.
已完成
1 期
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsPeripheral T-cell LymphomaNCT02809573Chipscreen Biosciences, Ltd.30
招募中
1 期
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1Muscular Dystrophy, FacioscapulohumeralNCT06131983Sarepta Therapeutics, Inc.60